Miriplatin Explained

Drug Name:	Miriplatin
Tradename:	Miripla
Legal Status:	Rx in Japan
Cas Number:	141977-79-9
Pubchem:	9832045
Unii:	780F0P8N4I
Chemspiderid:	8007775
Kegg:	D06294
Iupac Name:	Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
C:	34
H:	68
N:	2
O:	4
Pt:	1
Smiles:	CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]
Stdinchikey:	BGIHRZPJIYJKAZ-BLUNCNMSSA-L
Stdinchi:	1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).^{[1] [2]} Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.^[1]

See also

• Oxaliplatin

External links

• Development of Miriplatin, a Novel Antitumor Platinum for Hepatocellular Carcinoma

Notes and References

1. Web site: Miriplatin . Inxight Drugs . National Center for Advancing Translational Sciences, National Institutes of Health .
2. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T . 6 . Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial . Journal of Gastroenterology . 53 . 2 . 281–290 . February 2018 . 28766016 . 5846877 . 10.1007/s00535-017-1374-6 . Miriplatin TACE Study Group .